v3.25.4

Consolidated Statements of Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Statement of Comprehensive Income [Abstract]
Product revenues, net	$ 606,423	$ 363,707	$ 305,208
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	Product [Member]	Product [Member]	Product [Member]
Operating expenses:
Cost of product revenues (excluding amortization of intangible assets)	$ 122,938	$ 85,742	$ 65,573
Cost, Product and Service [Extensible Enumeration]	Product [Member]	Product [Member]	Product [Member]
Research and development	$ 771,093	$ 598,367	$ 571,011
Selling, general and administrative	701,167	461,116	344,501
Amortization of intangible assets	6,001	5,052	5,052
Change in fair value of deferred and contingent consideration	251,993	91,682	28,697
Total operating expenses	1,853,192	1,241,959	1,014,834
Operating loss	(1,246,769)	(878,252)	(709,626)
Investment income	60,656	53,307	42,132
Interest expense	(83,795)	(84,913)	(81,694)
Change in fair value of interest rate swap	0	(236)	320
Other (expense) income, net	(1,841)	29	1,856
Loss before income taxes	(1,271,749)	(910,065)	(747,012)
Provision for income taxes	5,026	3,707	2,555
Net loss	$ (1,276,775)	$ (913,772)	$ (749,567)
Basic net loss per share (in dollars per share)	$ (6.42)	$ (5.57)	$ (5.34)
Diluted net loss per share (in dollars per share)	$ (6.42)	$ (5.57)	$ (5.34)
Weighted average basic common shares outstanding (in shares)	199,014	164,043	140,433
Weighted average diluted common shares outstanding (in shares)	199,014	164,043	140,433
Net loss, basic	$ (1,276,775)	$ (913,772)	$ (749,567)
Net loss, diluted	(1,276,775)	(913,772)	(749,567)
Other comprehensive income (loss):
Foreign currency translation gains (losses)	3,306	(1,855)	(2,214)
Unrealized gain on marketable securities	444	311	713
Total comprehensive loss	$ (1,273,025)	$ (915,316)	$ (751,068)

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-11

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-24

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476148/220-40-50-12

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Name Accounting Standards Codification
-Section 55
-Paragraph 40
-SubTopic 30
-Topic 350
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482640/350-30-55-40

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482686/350-30-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476148/220-40-50-6

INSMED Inc 10-K